Mateos, Maria-Victoria, Weisel, Katja ORCID: 0000-0001-9422-6614, De Stefano, Valerio ORCID: 0000-0002-5178-5827, Goldschmidt, Hartmut, Delforge, Michel, Mohty, Mohamad ORCID: 0000-0002-7264-808X, Cavo, Michele, Vij, Ravi, Lindsey-Hill, Joanne, Dytfeld, Dominik, Angelucci, Emanuele, Perrot, Aurore ORCID: 0000-0003-0131-8689, Benjamin, Reuben ORCID: 0000-0003-1434-0594, van de Donk, Niels W. C. J., Ocio, Enrique M., Scheid, Christof, Gay, Francesca, Roeloffzen, Wilfried, Rodriguez-Otero, Paula, Broijl, Annemiek, Potamianou, Anna, Sakabedoyan, Caline, Semerjian, Maria, Keim, Sofia, Strulev, Vadim, Schecter, Jordan M., Vogel, Martin, Wapenaar, Robert, Nesheiwat, Tonia, San-Miguel, Jesus, Sonneveld, Pieter, Einsele, Hermann and Moreau, Philippe (2022). LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia, 36 (5). S. 1371 - 1377. LONDON: SPRINGERNATURE. ISSN 1476-5551

Full text not available from this repository.

Abstract

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, >= 3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 months (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Mateos, Maria-VictoriaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weisel, KatjaUNSPECIFIEDorcid.org/0000-0001-9422-6614UNSPECIFIED
De Stefano, ValerioUNSPECIFIEDorcid.org/0000-0002-5178-5827UNSPECIFIED
Goldschmidt, HartmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Delforge, MichelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohty, MohamadUNSPECIFIEDorcid.org/0000-0002-7264-808XUNSPECIFIED
Cavo, MicheleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vij, RaviUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lindsey-Hill, JoanneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dytfeld, DominikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Angelucci, EmanueleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Perrot, AuroreUNSPECIFIEDorcid.org/0000-0003-0131-8689UNSPECIFIED
Benjamin, ReubenUNSPECIFIEDorcid.org/0000-0003-1434-0594UNSPECIFIED
van de Donk, Niels W. C. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ocio, Enrique M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gay, FrancescaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roeloffzen, WilfriedUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rodriguez-Otero, PaulaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Broijl, AnnemiekUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Potamianou, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sakabedoyan, CalineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Semerjian, MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Keim, SofiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Strulev, VadimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schecter, Jordan M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vogel, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wapenaar, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nesheiwat, ToniaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
San-Miguel, JesusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sonneveld, PieterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Einsele, HermannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moreau, PhilippeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-698567
DOI: 10.1038/s41375-022-01531-2
Journal or Publication Title: Leukemia
Volume: 36
Number: 5
Page Range: S. 1371 - 1377
Date: 2022
Publisher: SPRINGERNATURE
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69856

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item